OSKM induced c-Jun overexpression of liver cancer cell reprogramming

SU Ming HAN Shuo ZHANG Ming-zhi LI Rui-zhi WEI Shi-ruo ZENG Wo-tan LIU Jin-wen SHEN Li*

doi:10.16098/j.issn.0529-1356.2017.03.008

PDF(847 KB)

Acta Anatomica Sinica ›› 2017, Vol. 48 ›› Issue (3) : 296-302. DOI: 10.16098/j.issn.0529-1356.2017.03.008

Cancer Biology

OSKM induced c-Jun overexpression of liver cancer cell reprogramming

SU Ming¹HAN Shuo¹ZHANG Ming-zhi¹LI Rui-zhi¹ WEI Shi-ruo¹ ZENG Wo-tan² LIU Jin-wen²SHEN Li ^1*

Author information +

History +

Abstract

Objective To establish an OSKM induced C3A-c-Jun of liver cancer reprogrammed cell line, and to explore the effects of exogenous c-Jun on liver cancer cell reprogramming. Methods OSKM was utilized to induce C3A-c-Jun to reprogram. Alkaline phosphatase staining, Real-time fluorescent quantitative polymerase chain reaction(Real-time PCR), Western blotting, and immunofluorescence technology were used to identify cells, and establish the C3A-c-Jun-iCSCs. Results C3A-c-Jun-iCSCs cells formed dome-shaped clones, in which cells were small, closely packed and multi-layered. Alkaline phosphatase staining was positive. They expressed pluripotent markers Oct4, Sox2, Nanog at the mRNA level and express OCT4, and SOX2 at the protein level. C3A-c-Jun-iCSCs had obviously higher gene expression of Sox2 compared with C3A-iCSCs, whatever in exogenous expression or endogenous expression. C-Jun continually expressed in the process of reprogramming. Conclusion OSKM induces C3A/C3A-c-Jun of liver cancer reprogramming and built the C3A-i-CSCs/C3A-c-J-un-iCSCs. Exogenous c-Jun has a promoting effect on liver cancer cell reprogramming process by upregulating Sox2, which then can activate downloaded genes.

Key words

c-Jun / Induce / Cancer stem cell / Reprogramming / Western blotting / C3A cell

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

SU Ming HAN Shuo ZHANG Ming-zhi LI Rui-zhi WEI Shi-ruo ZENG Wo-tan LIU Jin-wen SHEN Li. OSKM induced c-Jun overexpression of liver cancer cell reprogramming[J]. Acta Anatomica Sinica. 2017, 48(3): 296-302 https://doi.org/10.16098/j.issn.0529-1356.2017.03.008

References

［1］Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011,61(2):69-90.

［2］Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors［J］. Cell, 2006,126(4):663-676.

［3］Spangler B, Kappelmann M, Schittek B, et al. ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma［J］. Int J Cancer, 2012,130(12):2801-2811.

［4］Kappelmann M, Bosserhoff A, Kuphal S. AP-1/c-Jun transcription factors: regulation and function in malignant melanoma［J］. Eur J Cell Biol, 2014,93(1-2):76-81.

［5］Shaulian E. AP-1-The Jun proteins: oncogenes or tumor suppressors in disguise［J］? Cell Signal, 2010,22(6):894-899.

［6］Kuo KK, Lee KT, Chen KK, et al. Positive feedback loop of OCT4 and c-JUN expedites cancer stemness in liver cancer［J］. Stem Cells, 2016, doi: 10.1002/stem.2447.

［7］van Wenum M, Adam AA, Hakvoort TB, et al. Selecting cells for bioartificial liver devices and the importance of a 3D culture environment: A functional comparison between the HepaRG and C3A cell lines［J］. Int J Biol Sci, 2016,12(8):964-978.

［8］Han S, Guo J, Liu Y, et al. Knock out CD44 in reprogrammed liver cancer cell C3A increases CSCs stemness and promotes differentiation［J］. Oncotarget, 2015,6(42):44452-44465.

［9］Ulu?kan ?, Guinea-Viniegra J, Jimenez M, et al. Signalling in inflammatory skin disease by AP-1 (Fos/Jun)［J］. Clin Exp Rheumatol, 2015,33(4 Suppl 92):S44-49.

［10］Liu J, Han Q, Peng T, et al. The oncogene c-Jun impedes somatic cell reprogramming［J］. Nat Cell Biol, 2015,17(7):856-867.

［11］Zhou C, Yang X, Sun Y, et al. Comprehensive profiling reveals mechanisms of SOX2-mediated cell fate specification in human ESCs and NPCs［J］. Cell Res, 2016,26(2):171-189.

［12］Winiecka-Klimek M, Smolarz M, Walczak MP, et al. SOX2 and SOX2-MYC reprogramming process of fibroblasts to the neural stem cells compromised by senescence［J］. PLoS One, 2015,10(11):e0141688.

［13］Lundberg IV, Edin S, Ekl?f V, et al. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer［J］. BMC Cancer, 2016,16(1):471.

［14］Boumahdi S, Driessens G, Lapouge G, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma［J］. Nature, 2014,511(7508):246-250.

［15］Weina K, Utikal J. SOX2 and cancer: current research and its implications in the clinic［J］. Clin Transl Med, 2014(1),3:19.

［16］Leis O, Eguiara A, Lopez-Arribillaga E, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells［J］. Oncogene, 2012,31(11):1354-1365.

［17］Nichols J, Smith A. Naive and primed pluripotent states［J］. Cell Stem Cell, 2009,4(6):487-492.

［18］Li M, Liu GH, Izpisua BJC. Navigating the epigenetic landscape of pluripotent stem cells［J］. Nat Rev Mol Cell Biol, 2012,13(8):524-535.

［19］Shan ZhY, Wu B, Zhang Y, et al. Generation of induced pluripotent stem cells derived from parthenogenetic embryonic stem cells and reprogramming of imprinted genes［J］. Acta Anatomica Sinica, 2015,46(4):553-557.(in Chinese)

单智焱, 武玢, 张玥, 等. 孤雌胚胎干细胞来源的诱导多能干细胞的建立及对印记基因表达的影响［J］. 解剖学报,2015,46(4):553-557.

［20］van den Hurk M, Kenis G, Bardy C, et al. Transcriptional and epigenetic mechanisms of cellular reprogramming to induced pluripotency［J］. Epigenomics, 2016,8(8):1131-1149.

［21］G1adych M, Andrzejewska A, Oleksiewicz U, et al. Epigenetic mechanisms of induced pluripotency［J］. Contemp Oncol (Pozn), 2015,19(1A):A30-38.

［22］Ohnishi K, Semi K, Yamamoto T, et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation［J］. Cell, 2014, 156(4): 663-677.

［23］Guo Y, Liu S, Wang P, et al. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas［J］. Histopathology, 2011, 59(4): 763-775.

［24］Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer［J］. Oncogene, 2010, 29(14): 2153-2159.